Takeda Pharmaceutical Q2 2024 GAAP EPS ¥134.00 Up From ¥111.00 YoY, Sales ¥.176T Beat ¥1.084T Estimate
Portfolio Pulse from Benzinga Newsdesk
Takeda Pharmaceutical reported a significant increase in Q2 2024 earnings and sales, with EPS rising by 20.72% year-over-year and sales surpassing analyst estimates by 8.48%.
October 31, 2024 | 6:23 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Takeda Pharmaceutical's Q2 2024 earnings report shows a 20.72% increase in EPS and sales beating estimates by 8.48%, indicating strong financial performance.
The significant year-over-year increase in EPS and the fact that sales exceeded analyst expectations suggest a strong financial performance, likely leading to a positive short-term impact on Takeda's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100